We describe a possible clinical interaction between topiramate (TPM) and carbamazepine modified release (CBZ-MR) in patients taking maximum tolerated doses of carbamazepine. Data are presented on 25 patients who contacted the epilepsy nurse specialist telephone helpline for advice after starting treatment with TPM. Thirteen male and 12 female patients, mean age 41 years (range 25-69 years), with localization-related epilepsy contacted the helplines, between November 1999 and March 2001, complaining of symptoms of antiepileptic drug intoxication after starting treatment with TPM. All were taking maximum tolerated doses of CBZ-MR before starting TPM. Sixteen of the patients were taking other antiepileptic drugs concomitantly with CBZ-MR and TPM. Symptoms of intoxication were similar to those previously experienced when maximum tolerated doses of CBZ-MR were exceeded. Symptoms resolved when concomitant CBZ-MR doses were reduced, enabling further dose escalation of TPM. To our knowledge, neither clinical nor pharmacological interactions between CBZ and TPM have been described previously in man. These data suggest that such an interaction may be of clinical importance, and that reduction of the CBZ dose may enable optimization of the dose of TPM, improving seizure control.
INTRODUCTION
Clinical nurse specialists in epilepsy are both expert and readily accessible to patients. Open access to advice from specialist nurses, who are often involved with titration of antiepileptic drugs, enables patients to report adverse effects, which may otherwise go unrecorded between outpatient visits. Carbamazepine (CBZ) is an antiepileptic frequently used in conjunction with topiramate (TPM) to treat seizures. We report on 25 patients who contacted the epilepsy specialist nurse services in Sheffield and Barnsley. All were taking maximum tolerated doses of carbamazepine modified release (CBZ-MR) before introduction of TPM treatment. All complained of symptoms of intoxication during upward titration of TPM. In our opinion, the symptoms suggested intoxication with CBZ-MR rather than TPM, and all resolved on reduction of the concomitant CBZ-MR dose enabling continued upward titration of TPM.
CASE REPORTS Case 1
A 47-year-old man with localization-related epilepsy and left hemiparesis following a childhood head injury, experienced approximately 12 complex partial seizures per month despite treatment with CBZ-MR at the maximum tolerated dose (1000 mg twice daily), which he tolerated well. TPM was therefore introduced at a dose of 25 mg daily, increasing in increments of 25 mg daily every second week.
Six weeks after starting treatment with TPM he contacted the epilepsy nurse specialists complaining of lethargy and sleepiness, effects previously experienced when taking CBZ-MR at higher doses. At this time he was taking TPM 25 mg twice daily. His daily CBZ-MR dose was reduced by 100 mg and, although the symptoms were less severe, they only resolved a week later when the dose of CBZ-MR was further reduced to 900 mg twice daily. Seizure control was improved and no further titration of TPM was necessary.
Case 2
A 69-year-old man with cryptogenic frontal lobe epilepsy continued to have approximately 20 complex partial seizures per month in spite of maximum tolerated doses of CBZ-MR (700 mg mane, 800 mg nocte) and phenytoin (300 mg nocte). TPM was introduced at a dose of 25 mg at night, which was to be increased in increments of 25 mg daily every 2-4 weeks.
However, after 12 days this man contacted the epilepsy nurse specialists complaining of dizziness, poor co-ordination and blurred vision. The dose of CBZ-MR was reduced to 700 mg twice daily, although he continued to titrate the TPM upwards, and the effects resolved. When symptoms of intoxication returned, further reduction of the dose of concomitant CBZ-MR again resulted in their prompt resolution. His seizure control improved on TPM 50 mg in the morning and 75 mg at night, CBZ-MR 600 mg twice daily and phenytoin 300 mg at night.
Summary of cases
Twenty five patients (13 male, 12 female), mean age 41 years (range 25-69 years) contacted the epilepsy specialist nursing services in either Sheffield or Barnsley, between November 1999 and February 2001 (Table 1) . Before adding TPM to their treatment regimen, all patients had gradually titrated their dose of CBZ-MR to the maximum tolerated (mean 900 mg twice daily, range 450 mg-2.8 g twice daily). Nine patients were prescribed CBZ-MR monotherapy, 13 patients were taking two concomitant antiepileptic drugs and two were on three regular concomitant antiepileptic drugs.
TPM 25 mg once daily, taken at night, was added to the treatment regimen of all patients with the exception of one who started on a dose of 25 mg twice daily. The TPM dosage was titrated upwards by 25 mg daily every 2-4 weeks in all but two patients. In one of these latter patients (patient 17) the dose was increased weekly; in the other (patient 16) documented details of drug titration are unclear. Symptoms of drug intoxication were evident at a mean daily dose of TPM 160 mg (range 25-800 mg). Lowering the dose of concomitant CBZ-MR by 100 mg daily reduced the adverse symptoms in all cases although, as the dose of TPM was increased, further reductions were necessary in many.
For two patients (patients 19 and 24) who approached their general practitioner, signs of drug intoxication were abated when the dose of TPM was reduced. However, following subsequent contact with the nurse specialist services, TPM was successfully titrated upwards once the dose of CBZ-MR had been reduced.
DISCUSSION
Patient follow-up can only be infrequent in doctormanaged epilepsy outpatient clinics because of patient numbers. In contrast, epilepsy nurse specialists are better placed to monitor the progress of patients and have the knowledge and skill to recognize unusual or novel patterns of drug interaction. This may be why we have been able to recognize this possible interaction between two commonly co-administered antiepileptic drugs.
The major mechanism of clinically significant pharmacokinetic drug interactions of antiepileptic drugs involves the inhibition or induction of drug metabolism. TPM is an inhibitor of CYP2C19 and an inducer of CYP3A 1 . In a study of antiepileptic drug interaction in mice, TPM 5 mg kg −1 was found to increase the free plasma level of CBZ 2 . This does not appear to occur in man. In patients with refractory partial epilepsy receiving chronic stable doses of CBZ, add-on therapy with TPM was found to have no significant effect on the pharmacokinetics of CBZ or its major metabolite, CBZ epoxide 3 . This was attributed to the lack of inhibitory effect of TPM on CYP3A4, the isoenzyme responsible for the metabolism of CBZ. In addition, TPM displaced neither CBZ nor CBZ epoxide from their plasma binding sites 3 . However, mean plasma TPM concentrations were ∼40% lower during concomitant CBZ administration when compared with monotherapy 3 . This was shown to be the result of a two-fold increase in TPM clearance during concomitant CBZ therapy when compared with TPM monotherapy, probably due to increased TPM metabolism 3 .
To our knowledge, a clinical or pharmacological interaction between CBZ and TPM has not been previously reported in man. This, in part, may be because drug regimens of patients taking TPM often involve polypharmacy, which confounds recognition of drug interactions. In addition, medical practitioners who are relatively inexperienced in the use of antiepileptic medications often undertake the monitoring of patients prescribed such drugs. They may not appreciate symptoms signifying intoxication and, therefore, attribute them to the most recently introduced drug. Consequently, it is possible that in many cases treatment with TPM is withdrawn unnecessarily on appearance of such symptoms to the patient's detriment. Recognition of the interaction between CBZ and TPM is of particular clinical importance as reduction of the CBZ dose may enable optimization of the dose of TPM, improving seizure control. We recommend that patients taking CBZ who experience drug intoxication after introduction of TPM are advised to reduce the dose of CBZ to enable upward titration of the dose of TPM.
To date, we have found no evidence of a clinical interaction between TPM and sodium valproate, lamotrigine or gabapentin. However, our data for an interaction of clinical significance between TPM and phenytoin or vigabatrin are more uncertain.
